Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Iryna Savelikhina (Ivano-Frankivsk, Ukraine), Iryna Savelikhina, Oleksandr Varunkiv, Mykola Ostrovskyy, Mariana Kulynych-Miskiv, Kseniia Ostrovska. The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment. Eur Respir J 2016; 48: Suppl. 60, 4072

Member's Comments

No comment yet.

Related content which might interest you: The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment Source: International Congress 2016 – Translational studies in lung disease Year: 2016 The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Macrolide effects on the prevention of COPD exacerbations Source: Eur Respir J 2012; 40: 485-494 Year: 2012 Effects of dexamethasone and anti-inflammatory drugs on inflammatory cytokines from bronchial epithelial cells of COPD patients Source: International Congress 2015 – New insights into lung disease pathogenesis Year: 2015 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 New anti-inflammatory activities of Alpha-1-Antitrypsin and their role in COPD Source: Annual Congress 2005 - Protease-antiprotease revisited Year: 2005 Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Exploitation of anti-inflammatory mechanisms for the treatment of severe asthma Source: Annual Congress 2005 - Mechanisms of resolution of inflammation Year: 2005 TNFalpha release by monocyte-derived macrophages at stable and exacerbation states in COPD Source: International Congress 2014 – COPD physiopathology Year: 2014 Role of systemic inflammation mediated by IL-6 and TNF-alpha cytokines in chronic obstructive pulmonary disease and its progression: A three year follow up study Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 COPD, an inflammatory systemic disease. Inflammatory parameters in a group of COPD patients Source: International Congress 2014 – Lung function, COPD and inflammation Year: 2014 Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 MIG and IP-10 levels in induced sputum of stable and exacerbated COPD patients Source: International Congress 2015 – Systemic and airway biomarkers Year: 2015 Changes of TNF-a level in bronchoalveolar fluid of patients with chronic obstructive pulmonary disease before and after the 30 days treatment with tiotropium bromide Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015 Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD) Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 IL-17A is specifically elevated in NTHi-associated AECOPD and end-stage COPD Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Pathology, inflammation and cytokines of severe asthma Source: Eur Respir Mon 2011; 51: 97-106 Year: 2011 PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Effect of tiotropium bromide on IFN-γ level: Results from 180-days study in moderate COPD patients with viral-induced exacerbations in anamnesis Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016